



*National Imaging Associates, Inc.	
Clinical guideline: BRACHYTHERAPY (Low Dose Radiation (LDR), High Dose Radiation (HDR), Selective Internal Radiation Therapy (SIRT, Electronic Brachytherapy)	Original Date: November 2013
CPT Codes: LDR: 77761, 77762, 77763, 77778, 77789 HDR: 77767, 77768, 77770, 77771, 77772 Electronic Brachytherapy: 0394T, 0395T	Last Revised Date: May 2023
Guideline Number: NIA_CG_224 - 1	Implementation Date: January 2024

GENERAL INFORMATION

- *It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.*
- *Where a specific clinical indication is not directly addressed in this guideline, medical necessity determination will be made based on widely accepted standard of care criteria. These criteria are supported by evidence-based or peer-reviewed sources such as medical literature, societal guidelines and state/national recommendations.*

Most requests for radiation therapy are addressed by NIA treatment site clinical guidelines. However, there may be requests that are not. For such requests, determinations will be made on a case-by-case basis utilizing the following guidelines (when applicable) but not limited to: National Comprehensive Cancer Network (NCCN), American Society for Radiation Oncology ASTRO (i.e., Model Policies; Evidence-Based Consensus Statement), ACR Appropriateness Criteria, American Society of Clinical Oncology (ASCO) and/or peer reviewed literature.

This guideline applies to other cancers not addressed by NIA treatment site clinical guidelines LDR (low dose rate brachytherapy) and HDR (high dose rate brachytherapy) must be requested separately and are not interchangeable.

Refer to applicable treatment site-specific guidelines for the management of primary malignancies. Applicable site-specific guidelines may include all or some of the sites below, depending on the specific program.

- Anal Cancer
- Bone Metastases
- Breast Cancer
- Cervical Cancer
- CNS Cancer
- Colon Cancer
- Rectal Cancer
- Endometrial Cancer
- Gastric Cancers
- Head and Neck Cancer
- Lung – Non-Small Cell
- Lung - Small Cell Lung Cancer
- Lymphoma - Hodgkin’s Lymphoma
- Lymphoma – Non-Hodgkin’s Lymphoma
- Pancreas Cancer
- Prostate Cancers

For metastasis to the brain, regardless of primary site, refer to the NIA clinical guideline for Central Nervous System (CNS). For metastasis to bone, refer to the NIA clinical guideline for Bone Metastases.

For all other metastases, refer to the NIA clinical guideline for Metastatic Disease.

TREATMENT OPTIONS (WILL BE REVIEWED ON A CASE-BY-CASE BASIS) REQUIRING PHYSICIAN REVIEW

- Brachytherapy for sites beyond those listed above may be approvable with submission of supportive documentation.¹
- Intracavitary balloon catheter brain brachytherapy for malignant gliomas or metastasis to the brain is considered *investigational*.
- Selective Internal Radiation Therapy (SIRT), also known as radioembolization with microsphere brachytherapy device (RMBD) and transarterial radioembolization, uses microscopic radioactive spheres to deliver radiation to the tumor site. Treatment is delivered through catheter injection of radioactive Yttrium-90 (90Y) microspheres into the hepatic artery.
 - Indications for SIRT include:²⁻⁴
 - Unresectable metastatic liver tumors – see **“Metastatic Disease Guideline”**
 - Unresectable metastatic liver tumors from primary colorectal cancer see **“Metastatic Disease Guideline”**
 - Unresectable primary hepatocellular carcinoma²
 - Unresectable neuroendocrine tumors
 - Absolute Contraindication:⁵
 - Fulminant liver failure (absolute)
 - Considerations/Relative Contraindications:⁵
 - The tumor burden should be liver dominant, not necessarily exclusive to the liver

- Patients should also have a performance status that will allow them to benefit from such therapy
 - A life expectancy of at least 3 months
 - Excessive tumor burden in the liver with greater than 50% to 70% of the parenchyma replaced by tumor
 - Total bilirubin greater than 2 mg/dL (in the absence of obstructive cause), which indicates severe liver function impairment. Nonobstructive bilirubin elevations may indicate that liver metastases have caused liver impairment to the degree that risks outweigh benefits for this therapy. In contrast, patients with HCC and elevated bilirubin may be treated with radioembolization if a segmental or subsegmental infusion can be performed
 - Prior radiation therapy to the liver or upper abdomen that included a significant volume of the liver
- The use of electronic brachytherapy for basal cell and squamous cell cancers of the skin (of non-melanomatous skin cancers) and benign skin conditions are considered investigational and experimental at this time.^{6,7}
- Coronary Artery Brachytherapy⁸⁻¹⁴
 - Intravascular brachytherapy for coronary arteries is medically necessary when used as an adjunct to percutaneous coronary intervention for treatment of in-stent restenosis in a native coronary artery bare-metal stent or for drug-eluting stent
 - All other uses of brachytherapy for coronary arteries are considered investigational
- Plaque brachytherapy is a common form of definitive radiotherapy for uveal melanoma¹⁵⁻¹⁷
 - It is appropriate for patients with tumors ≤ 19 mm in largest basal diameter and ≤ 10 mm in thickness. It may be used selectively in patients with larger tumors
 - It is appropriate both as an upfront therapy after initial diagnosis, or after local recurrence following a prior local therapy
 - Iodine-125 Collaborative Ocular Melanoma Study (COMS) plaques: 85Gy should be prescribed to the apex of the tumor at low dose rate (≥ 0.6 Gy/h). The plaque margin on the tumor border should be ≥ 2 mm when feasible. The exception is for tumors near the optic nerve.
 - Non-COMS Iodine-125, and other radioisotopes (e.g., ruthenium-106, palladium-103, strontium-90, cobalt-60, cesium-131): 60-100Gy may be prescribed at low dose rate to the tumor apex.

REFERENCES

1. American Society for Radiation Oncology. ASTRO model policies: Brachytherapy. American Society for Radiation Oncology (ASTRO). Updated January 25, 2019. Accessed December 6, 2022. <https://www.astro.org/ASTRO/media/ASTRO/Daily%20Practice/PDFs/BrachyModelPolicy.pdf>
2. Kouri BE, Abrams RA, Al-Refaie WB, et al. ACR Appropriateness Criteria Radiologic Management of Hepatic Malignancy. *J Am Coll Radiol*. Mar 2016;13(3):265-73. doi:10.1016/j.jacr.2015.12.001
3. Hong K, Akinwande O, Bodei L, et al. ACR-ABS-ACNM-ASTRO-SIR-SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies. *Brachytherapy*. May-Jun 2021;20(3):497-511. doi:10.1016/j.brachy.2021.01.006
4. Tom MC, Hepel JT, Patel R, et al. The American Brachytherapy Society consensus statement for electronic brachytherapy. *Brachytherapy*. May-Jun 2019;18(3):292-298. doi:10.1016/j.brachy.2018.10.006
5. Negi SI, Torguson R, Gai J, et al. Intracoronary Brachytherapy for Recurrent Drug-Eluting Stent Failure. *JACC Cardiovasc Interv*. Jun 27 2016;9(12):1259-1265. doi:10.1016/j.jcin.2016.03.018
6. Ohri N, Sharma S, Kini A, et al. Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents. *Adv Radiat Oncol*. Jan-Mar 2016;1(1):4-9. doi:10.1016/j.adro.2015.12.002
7. Ilyas I, Kumar A, Adalja D, et al. Intracoronary brachytherapy for the treatment of recurrent drug-eluting stent in-stent restenosis: A systematic review and meta-analysis. *World J Cardiol*. Apr 26 2021;13(4):95-102. doi:10.4330/wjc.v13.i4.95
8. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. *Brachytherapy*. Jan-Feb 2014;13(1):1-14. doi:10.1016/j.brachy.2013.11.008
9. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Melanoma: Cutaneous Version 1.2023. National Comprehensive Cancer Network (NCCN). Updated December 22, 2022. Accessed January 3, 2023. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf

POLICY HISTORY

Date	Summary
May 2023	<ul style="list-style-type: none"> • Added plaque brachytherapy for uveal melanoma • Updated references • Changed heading from “Treatment requiring physician review” to “Treatment options (will be reviewed on a case-by-case basis)” • Removed Additional Resources
January 2022	<ul style="list-style-type: none"> • Added absolute contraindication of fulminant liver failure • Added section on Considerations/Relative Contraindications, stating: <ul style="list-style-type: none"> ○ The tumor burden should be liver dominant, not necessarily exclusive to the liver ○ Patients should also have a performance status that will allow them to benefit from such therapy ○ A life expectancy of at least 3 months ○ Excessive tumor burden in the liver with greater than 50% to 70% of the parenchyma replaced by tumor ○ Total bilirubin greater than 2 mg/dL (in the absence of obstructive cause), which indicates severe liver function impairment. Nonobstructive bilirubin elevations may indicate that liver metastases have caused liver impairment to the degree that risks outweigh benefits for this therapy. In contrast, patients with HCC and elevated bilirubin may be treated with radioembolization if a segmental or subsegmental infusion can be performed ○ Prior radiation therapy to the liver or upper abdomen that included a significant volume of the liver



Reviewed / Approved by NIA Clinical Guideline Committee:

Disclaimer: *National Imaging Associates, Inc. (NIA) authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Evolent Health LLC subsidiaries including, but not limited to, National Imaging Associates (“NIA”). The policies constitute only the reimbursement and coverage guidelines of NIA. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. NIA reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.*

